Johnson & Johnson's much-hyped simeprevir picked up the unanimous support of FDA advisers on Thursday, moving the potential hepatitis C blockbuster one step closer to market as a who's who of drug developers advances next-generation therapies.
Soon after Xtandi hit the market last year, analysts were figuring that the prostate cancer drug would help pump up that market to $9.1 billion by 2021. And now, the drug has shown success in a Phase III trial eyeing Xtandi as a prechemo treatment for advanced prostate cancer.
The latest report on healthcare fraud settlements is out, this time from Taxpayers Against Fraud. And this time, as usual, Big Pharma features prominently. The anti-fraud group regularly totes up whistleblower settlements with federal and state governments, and we all know that drugmaker payments account for billions.
J&J and its partner Medivir earned a positive internal review at the FDA for simeprevir. But a substantial subpopulation of patients infected with a particular polymorphism variant likely won't benefit, leaving that field open to some big rivals contending for near-term approvals.
The U.S. is one of only two countries that allow direct-to-consumer (DTC) advertising of pharmaceuticals, and opinions on whether doing so is a good idea are all over the place, even among doctors....
Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...
Now that J&J has wrapped up the $1 billion acquisition of Aragon and its next-gen treatment for castration-resistant prostate cancer, the biotech's founders can devote themselves to a new startup that now has a $30 million venture bankroll to work with.
Johnson & Johnson's DePuy division took another small step this month toward addressing legions of lawsuits alleging it sold faulty metal-on-metal hips. The company "resolved" a case in New Jersey, at least the second against the company settled so far in October.
The calendar has finally caught up with Johnson & Johnson. Quarter after quarter, the healthcare giant watched its $21.3 billion Synthes acquisition prop up otherwise flagging medical device sales, but it's all come full circle in Q3, leaving J&J's slumping med tech revenue down 2% as the company looks to sell off its diagnostics business.
Many a drugmaker CEO would love to unveil pharma sales like Johnson & Johnson's in the third quarter. J&J's prescription drug revenue burgeoned by 9.9%, fueled by still-growing older meds like Remicade and newer debuts like the prostate cancer treatment Zytiga and blood thinner Xarelto. Total pharma sales for the period: $7 billion.